Arthritis, Rheumatoid Clinical Trial
Official title:
A Multicenter, Open-Label, Single-Arm Extension Study To Describe The Safety Of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 And MA21488 And Presenting An Indication Of Maintaining The Tocilizumab Treatment
This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with Rheumatoid Arthritis (RA). Participants who have completed the MA21488 (NCT00810199) core study and the ML21530 (NCT00754572) study and who could benefit from the study drug, according to the opinion of the investigator, will receive 8 milligram per kilogram (mg/kg) of intravenous (IV) tocilizumab every 4 weeks. The anticipated time on study treatment is 104 weeks.
Status | Completed |
Enrollment | 26 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participants who have completed their last visit ML21530 and MA21488 in core studies and that might benefit from treatment using the study drug according to the investigator's evaluation - Absence of an adverse event (AE) or current or recent laboratory finding that would prevent the use of the 8 mg/kg dose of the tocilizumab - Receiving outpatient treatment - For women who are not postmenopausal and are not surgically sterile: agreement to use at least one adequate method of contraception Exclusion Criteria: - Participants who have prematurely discontinued ML21530 and MA21488 core studies for any reason - MA21488 study participants who remained untreated with tocilizumab after it's discontinuation according to the treatment-free remission criteria from MA21488 study - Immunization with a live/attenuated vaccine since the last administration of the study drug in ML21530 and ML21488 core studies - Diagnosis after the last visit of the study ML21530 or after the last visit of the study MA21488 of a rheumatic autoimmune disease other than RA, including systemic erythematous lupus (SEL), mixed connective tissue disease (MCTD), scleroderma and polymyositis, or a significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjogren's Syndrome and/or nodulosis with RA are allowed - Diagnosis after the last visit in ML21530 study or after the last visit in MA21488 study of a rheumatic autoimmune disease and/or an inflammatory joint disease other than rheumatoid arthritis - Abnormal laboratory parameters at the baseline - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies - Evidences of a concomitant, serious and uncontrolled illness - Known active condition or a history of recurrent infections by bacteria, viruses, fungi, mycobacteria or other agents - Evidence of an active malignant disease, malignancies diagnosed in the last 10 years or breast cancer diagnosed in the last 20 years - Uncontrolled disease status, such as asthma or inflammatory bowel disease in which acute crises are usually treated with oral or parenteral corticosteroids - Current hepatic disease, as determined by the Investigator - Active tuberculosis (TB) requiring treatment in the previous three years. Participants should be screened for latent TB according to local practice guidelines and should not be admitted into the study if latent TB is detected. Participants must not present any evidence of active TB infection at the enrollment. Participants treated for tuberculosis without recurrence in three years are allowed - History of drugs of abuse since the inclusion in the ML21530 and MA21488 core studies |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Adverse Events | Approximately 3 years | No | |
Primary | Percentage of Participants With Adverse Events Leading to Dose Modification or Study Discontinuation | Approximately 3 years | No | |
Primary | Percentage of Participants With Adverse Events of Special Interest | Approximately 3 years | Yes | |
Secondary | Mean Change From Baseline in Disease Activity Index 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Mean Change From Baseline in Tender Joint Count (TJC) at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Mean Change From Baseline in Swollen Joint Count (SJC) at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Mean Change From Baseline Score for Global Evaluation of Disease Activity by the Patient Using Visual Analog Scale (VAS) at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Mean Change From Baseline Score for Global Evaluation of Disease Activity by the Physician Using VAS at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 | No | |
Secondary | Mean Change From Baseline Score for Participant's Pain Assessment Using VAS at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Mean Change From Baseline Score for Health Assessment Questionnaire - Disability Index (HAQ - DI) at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Means Change From Baseline in C-Reactive Protein (CRP) Level at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No | |
Secondary | Means Change From Baseline in Erythrocyte Sedimentation Rate at specified time points | From Baseline to Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104 and four follow up visits every 4 week after Week 104 (up to approximately 3 years) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |